Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.56 USD
Change Today +0.08 / 0.59%
Volume 32.5K
OXFD On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

oxford immunotec global plc (OXFD) Snapshot

Open
$13.52
Previous Close
$13.48
Day High
$13.89
Day Low
$13.00
52 Week High
11/4/14 - $15.61
52 Week Low
12/12/14 - $10.01
Market Cap
305.5M
Average Volume 10 Days
37.0K
EPS TTM
$-1.38
Shares Outstanding
22.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Related News

No related news articles were found.

oxford immunotec global plc (OXFD) Related Businessweek News

No Related Businessweek News Found

oxford immunotec global plc (OXFD) Details

Oxford Immunotec Global PLC, a diagnostics company, develops and commercializes proprietary tests for the management of immune-regulated conditions in the United States, Europe, Japan, and China. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immunologically controlled diseases. Its solution includes SPOT.TB test, a single-cell based method for identifying latent tuberculosis infection. The company was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

270 Employees
Last Reported Date: 08/4/15
Founded in 2002

oxford immunotec global plc (OXFD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $406.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $255.0K
Chief Operations Officer
Total Annual Compensation: $268.5K
Chief Commercial Officer
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2014.

oxford immunotec global plc (OXFD) Key Developments

Oxford Immunotec Global PLC Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Third Quarter and Full Year 2015

Oxford Immunotec Global PLC reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $14.3 million, representing 21% growth over the second quarter 2014 revenue of $11.8 million. LBITDA was $6.8 million compared to $5.8 million in the second quarter of 2014. Adjusted LBITDA was $6.5 million compared to $4.9 million in the same period in 2014. Net loss was $7.3 million, or $0.33 per share, compared to $6.2 million, or $0.36 per share, in the second quarter of 2014. Loss from operations was $6.61 million compared to $6.03 million a year ago. Loss before income taxes was $7.29 million compared to $6.24 million a year ago. For the six months, total revenue was $28.05 million compared to $24.06 million a year ago. Adjusted LBITDA was $11.52 million compared to $7.32 million a year ago. Loss from operations was $13.13 million compared to $8.97 million a year ago. Loss before income taxes was $13.56 million compared to $9.36 million a year ago. Net loss was $13.61 million or $0.64 per basic and diluted share compared to $9.39 million or $0.54 per basic and diluted share a year ago. The company provided revenue guidance for the third quarter and full year 2015. The company expects to report revenue of between $16.8 and $17.6 million for the third quarter of 2015. The company expects to report full year 2015 revenue of between $61 and $64 million, representing 23%-29% year-over-year growth. The company expects revenue to increase 29% to 35% for the year using constant exchange rates.

Oxford Immunotec Global PLC to Report Q2, 2015 Results on Aug 04, 2015

Oxford Immunotec Global PLC announced that they will report Q2, 2015 results at 9:00 AM, GMT Standard Time on Aug 04, 2015

Oxford Immunotec Global PLC, Q2 2015 Earnings Call, Aug 04, 2015

Oxford Immunotec Global PLC, Q2 2015 Earnings Call, Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXFD:US $13.56 USD +0.08

OXFD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXFD.
View Industry Companies
 

Industry Analysis

OXFD

Industry Average

Valuation OXFD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD IMMUNOTEC GLOBAL PLC, please visit www.oxfordimmunotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.